Literature DB >> 32553791

Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.

Shashidhar S Jatiani1, Adolfo Aleman2, Deepu Madduri2, Ajai Chari2, Hearn Jay Cho2, Shambavi Richard2, Joshua Richter2, Joshua Brody2, Sundar Jagannath2, Samir Parekh3.   

Abstract

Entities:  

Keywords:  Anakinra; CAR-T cell therapy; Cytokine release syndrome; Multiple myeloma; Tocilizumab

Year:  2020        PMID： 32553791      PMCID： PMC7484011          DOI： 10.1016/j.clml.2020.04.020

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  12 in total

1.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Authors:  Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  J Clin Oncol       Date:  2017-07-17       Impact factor: 44.544

2.  Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  Julie C Fitzgerald; Scott L Weiss; Shannon L Maude; David M Barrett; Simon F Lacey; J Joseph Melenhorst; Pamela Shaw; Robert A Berg; Carl H June; David L Porter; Noelle V Frey; Stephan A Grupp; David T Teachey
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

3.  FDA Approves Second CAR T-cell Therapy.

Authors: 
Journal:  Cancer Discov       Date:  2017-11-07       Impact factor: 39.397

4.  First-Ever CAR T-cell Therapy Approved in U.S.

Authors: 
Journal:  Cancer Discov       Date:  2017-09-08       Impact factor: 39.397

5.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

Review 6.  IL-6 as a keystone cytokine in health and disease.

Authors:  Christopher A Hunter; Simon A Jones
Journal:  Nat Immunol       Date:  2015-05       Impact factor: 25.606

7.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.

Authors:  Margherita Norelli; Barbara Camisa; Giulia Barbiera; Laura Falcone; Ayurzana Purevdorj; Marco Genua; Francesca Sanvito; Maurilio Ponzoni; Claudio Doglioni; Patrizia Cristofori; Catia Traversari; Claudio Bordignon; Fabio Ciceri; Renato Ostuni; Chiara Bonini; Monica Casucci; Attilio Bondanza
Journal:  Nat Med       Date:  2018-05-28       Impact factor: 53.440

8.  CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

Authors:  Theodoros Giavridis; Sjoukje J C van der Stegen; Justin Eyquem; Mohamad Hamieh; Alessandra Piersigilli; Michel Sadelain
Journal:  Nat Med       Date:  2018-05-28       Impact factor: 53.440

9.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

Review 10.  CAR T Cell Toxicity: Current Management and Future Directions.

Authors:  Lucrecia Yáñez; Miriam Sánchez-Escamilla; Miguel-Angel Perales
Journal:  Hemasphere       Date:  2019-03-29
View more
  9 in total

Review 1.  Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.

Authors:  Ajay Major; Jennifer Collins; Caroline Craney; Alisa K Heitman; Emily Bauer; Elizabeth Zerante; Wendy Stock; Michael R Bishop; Jagoda Jasielec
Journal:  Leuk Lymphoma       Date:  2021-02-09

2.  Anakinra utilization in refractory pediatric CAR T-cell associated toxicities.

Authors:  Caroline Diorio; Anant Vatsayan; Aimee C Talleur; Colleen Annesley; Jennifer J Jaroscak; Haneen Shalabi; Amanda K Ombrello; Michelle Hudspeth; Shannon L Maude; Rebecca A Gardner; Nirali N Shah
Journal:  Blood Adv       Date:  2022-06-14

3.  A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.

Authors:  Bo Wang; Oliver Van Oekelen; Tarek H Mouhieddine; Diane Marie Del Valle; Joshua Richter; Hearn Jay Cho; Shambavi Richard; Ajai Chari; Sacha Gnjatic; Miriam Merad; Sundar Jagannath; Samir Parekh; Deepu Madduri
Journal:  J Hematol Oncol       Date:  2020-07-14       Impact factor: 17.388

Review 4.  Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.

Authors:  Emma C Morris; Sattva S Neelapu; Theodoros Giavridis; Michel Sadelain
Journal:  Nat Rev Immunol       Date:  2021-05-17       Impact factor: 53.106

Review 5.  Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.

Authors:  Antonio Nenna; Myriam Carpenito; Camilla Chello; Pierluigi Nappi; Ombretta Annibali; Bruno Vincenzi; Francesco Grigioni; Massimo Chello; Francesco Nappi
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 6.  Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy.

Authors:  Puri Ferreros; Isabel Trapero
Journal:  Diseases       Date:  2022-07-06

7.  The use of ICU resources in CAR-T cell recipients: a hospital-wide study.

Authors:  Sandrine Valade; Michael Darmon; Lara Zafrani; Eric Mariotte; Virginie Lemiale; Swann Bredin; Guillaume Dumas; Nicolas Boissel; Florence Rabian; André Baruchel; Isabelle Madelaine; Jérôme Larghero; Anne Brignier; Etienne Lengliné; Stéphanie Harel; Bertrand Arnulf; Roberta Di Blasi; Catherine Thieblemont; Elie Azoulay
Journal:  Ann Intensive Care       Date:  2022-08-17       Impact factor: 10.318

Review 8.  Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Authors:  Dong-Rui Wang; Xian-Lin Wu; Ying-Li Sun
Journal:  Signal Transduct Target Ther       Date:  2022-09-19

Review 9.  CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities.

Authors:  Joseph W Fischer; Nirjal Bhattarai
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.